These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31314518)

  • 1. Identification of
    Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of imidazo[1,2-
    Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
    Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
    Chang Y; Xu S; Ding K
    J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
    Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
    Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
    Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
    Liu C; Lin J; Langevine C; Smith D; Li J; Tokarski JS; Khan J; Ruzanov M; Strnad J; Zupa-Fernandez A; Cheng L; Gillooly KM; Shuster D; Zhang Y; Thankappan A; McIntyre KW; Chaudhry C; Elzinga PA; Chiney M; Chimalakonda A; Lombardo LJ; Macor JE; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2021 Jan; 64(1):677-694. PubMed ID: 33370104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
    Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
    J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
    Wang J; Batista VS; Bunick CG
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.
    Cheng C; Zhou M; Zhang P; Qian W; Chen L; Chen G
    Biomed Res Int; 2022; 2022():6383893. PubMed ID: 35586808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
    Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel N-(methyl-d
    Liu F; Wang B; Liu Y; Shi W; Hu Z; Chang X; Tang X; Zhang Y; Xu H; He Y
    Bioorg Med Chem Lett; 2023 Apr; 86():129235. PubMed ID: 36907336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
    Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
    Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
    Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
    Rusiñol L; Puig L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.